GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sotac Pharmaceuticals Ltd (NSE:SOTAC) » Definitions » Beneish M-Score

Sotac Pharmaceuticals (NSE:SOTAC) Beneish M-Score : -0.47 (As of Jan. 18, 2025)


View and export this data going back to 2023. Start your Free Trial

What is Sotac Pharmaceuticals Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -0.47 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Sotac Pharmaceuticals's Beneish M-Score or its related term are showing as below:

NSE:SOTAC' s Beneish M-Score Range Over the Past 10 Years
Min: -0.47   Med: -0.47   Max: -0.47
Current: -0.47

During the past 5 years, the highest Beneish M-Score of Sotac Pharmaceuticals was -0.47. The lowest was -0.47. And the median was -0.47.


Sotac Pharmaceuticals Beneish M-Score Historical Data

The historical data trend for Sotac Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sotac Pharmaceuticals Beneish M-Score Chart

Sotac Pharmaceuticals Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24
Beneish M-Score
- - - - -0.47

Sotac Pharmaceuticals Quarterly Data
Mar20 Mar21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -0.47 - -

Competitive Comparison of Sotac Pharmaceuticals's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Sotac Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sotac Pharmaceuticals's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sotac Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Sotac Pharmaceuticals's Beneish M-Score falls into.



Sotac Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Sotac Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.3024+0.528 * 1.0906+0.404 * 1.6998+0.892 * 1.34+0.115 * 1.167
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.5335+4.679 * 0.193712-0.327 * 0.7289
=-0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was ₹263 Mil.
Revenue was ₹1,038 Mil.
Gross Profit was ₹235 Mil.
Total Current Assets was ₹606 Mil.
Total Assets was ₹1,053 Mil.
Property, Plant and Equipment(Net PPE) was ₹387 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹31 Mil.
Selling, General, & Admin. Expense(SGA) was ₹7 Mil.
Total Current Liabilities was ₹437 Mil.
Long-Term Debt & Capital Lease Obligation was ₹121 Mil.
Net Income was ₹43 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹-161 Mil.
Total Receivables was ₹151 Mil.
Revenue was ₹775 Mil.
Gross Profit was ₹191 Mil.
Total Current Assets was ₹471 Mil.
Total Assets was ₹736 Mil.
Property, Plant and Equipment(Net PPE) was ₹240 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹23 Mil.
Selling, General, & Admin. Expense(SGA) was ₹10 Mil.
Total Current Liabilities was ₹458 Mil.
Long-Term Debt & Capital Lease Obligation was ₹78 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(262.877 / 1038.305) / (150.625 / 774.832)
=0.253179 / 0.194397
=1.3024

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(191.113 / 774.832) / (234.827 / 1038.305)
=0.246651 / 0.226164
=1.0906

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (606.454 + 387.232) / 1053.269) / (1 - (471.387 + 240.495) / 736.39)
=0.05657 / 0.033281
=1.6998

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1038.305 / 774.832
=1.34

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(22.777 / (22.777 + 240.495)) / (31.005 / (31.005 + 387.232))
=0.086515 / 0.074133
=1.167

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(6.838 / 1038.305) / (9.565 / 774.832)
=0.006586 / 0.012345
=0.5335

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((121.311 + 437.3) / 1053.269) / ((77.689 + 458.116) / 736.39)
=0.530359 / 0.72761
=0.7289

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(42.813 - 0 - -161.218) / 1053.269
=0.193712

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Sotac Pharmaceuticals has a M-score of -0.47 signals that the company is likely to be a manipulator.


Sotac Pharmaceuticals Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Sotac Pharmaceuticals's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Sotac Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
Plot No. PF-21, Near ACME Pharma, Opposite Teva Pharma Sanand GIDC-II, Sanand, Ahmedabad, GJ, IND, 382110
Sotac Pharmaceuticals Ltd is a pharma manufacturer, specializing in the manufacturing of a wide range of pharmaceutical products such as Non-Beta-Lactam (general) tablets, beta-lactam coated tablets, beta-lactam uncoated tablets, Non-Beta-Lactam (general) capsules, beta-lactam capsules, oral liquid, dry syrup and external preparations such as nasal spray, relief spray, and cream.

Sotac Pharmaceuticals Headlines

No Headlines